| 4906 |
Centers for Disease Control and Prevention |
Html |
en |
Clinical Laboratories Role in the Search and Containment of VRSA - HAI |
null |
| prompt recognition | 0.381547 |
| VRE | 0.392404 |
| public health authorities | 0.546342 |
| assistance contact CDC | 0.460933 |
| Disease Control | 0.400983 |
| Organisms In Healthcare | 0.373729 |
| Healthcare Infection Control | 0.523412 |
| Staphylococcus aureus | 0.475209 |
| VRSA strains | 0.645354 |
| VRSA | 0.967261 |
| public health partners | 0.442152 |
| home healthcare | 0.378044 |
| Vancomycin-Intermediate/Resistant Staphylococcus aureus | 0.456873 |
| infection control personnel | 0.559268 |
| vancomycin resistant Staphylococcus | 0.498342 |
| clinical laboratories | 0.449606 |
| important role | 0.383022 |
| patient-care personnel | 0.382106 |
| Vancomycin Resistance Recommendations | 0.439054 |
| state public health | 0.438929 |
| testing methodologies | 0.376099 |
| infection control guidelines | 0.512995 |
| healthcare providers | 0.37548 |
| Infection Control Practices | 0.605152 |
| United States | 0.381326 |
|
| methicillin-resistant Staphylococcus auerus | 0.464377 |
| infection control | 0.897868 |
| 13th case | 0.382856 |
| sample algorithm | 0.375827 |
| Advisory Committee | 0.428055 |
| Healthcare Quality Promotion | 0.42999 |
| infection control precautions | 0.630577 |
| Appropriate antimicrobial prescribing | 0.42499 |
| testing results | 0.376839 |
| genetic material | 0.374212 |
| VRSA infection | 0.745629 |
| public health | 0.583462 |
| VRSA cases | 0.718891 |
| vancomycin-resistant enterococci | 0.390252 |
| confirmatory susceptibility tests | 0.435043 |
| VRSA visit | 0.635987 |
| Practices Advisory Committee | 0.41886 |
| Hospital Infection Control | 0.506138 |
| infection control recommendations | 0.526019 |
| isolate types | 0.375656 |
| U.S. VRSA case | 0.699235 |
| appropriate infection control | 0.529185 |
| healthcare settings | 0.431235 |
| important opportunity | 0.382077 |
|
CLICK HERE |
| 5153 |
Centers for Disease Control and Prevention |
Html |
en |
Massachusetts Activities to Prevent HAIs |
null |
| HAI Data | 0.638299 |
| Healthcare-associated Infections | 0.536848 |
| HAI Detection | 0.67288 |
| email address | 0.650078 |
| CDI | 0.431652 |
| Hemodialysis BSI | 0.630568 |
| navigation Skip | 0.666971 |
| recent work | 0.651685 |
| Carbapenem-resistant Enterobacteriaceae | 0.536287 |
| Infection Prevention | 0.573047 |
| Clostridium difficile infection | 0.690155 |
| Data Validation | 0.814459 |
| Hemodialysis Bloodstream Infections | 0.76359 |
| list Skip | 0.668625 |
|
| monthly update | 0.665387 |
| page options Skip | 0.794235 |
| Coordinated Prevention | 0.551965 |
| Infection Control Assessment | 0.670374 |
| ELC HAI-funded Activities | 0.669338 |
| infectious disease | 0.66817 |
| Antimicrobial Resistance | 0.545261 |
| Laboratory Capacity | 0.537362 |
| CRE | 0.440394 |
| Initial Implementation | 0.523868 |
| information | 0.421861 |
| CLABSI Validation Guidance | 0.671687 |
| HAI Prevention Infrastructure | 0.92246 |
|
CLICK HERE |
| 6505 |
Centers for Disease Control and Prevention |
Html |
en |
Testing for Vaccine Adverse Events - Yellow Fever |
Information on Yellow Fever. Provided by the U.S. Centers for Disease Control and Prevention. |
| Page | 0.331099 |
| acute-phase sera | 0.402156 |
| recent yellow fever | 0.629891 |
| yellow fever vaccine | 0.763053 |
| shipment | 0.317495 |
| systemic illness | 0.39696 |
| CDC/FDA | 0.317504 |
| patients | 0.316969 |
| extreme caution | 0.394774 |
| Polymerase chain reaction | 0.485176 |
| CDC Division | 0.449355 |
| previous reports | 0.405624 |
| potentially infected materials | 0.485259 |
| yellow fever vaccination | 0.812583 |
| Arbovirus Diseases | 0.397508 |
| overnight shipping | 0.386759 |
| Vector-Borne Diseases | 0.492293 |
| yellow fever | 0.930867 |
| Fort Collins | 0.384017 |
| fresh-frozen tissue samples | 0.479417 |
| anaphylaxis | 0.323231 |
| CDC medical officers | 0.526934 |
| following methods | 0.439885 |
| vaccine virus | 0.424711 |
|
| viral culture | 0.397464 |
| patient | 0.330259 |
| suspect cases | 0.408257 |
| CSF | 0.328834 |
| specimen | 0.32166 |
| CDC Submission Form | 0.522996 |
| VAERS | 0.369362 |
| fever vaccine-associated viscerotropic | 0.60357 |
| fever vaccine-associated neurologic | 0.609967 |
| recent recipients | 0.399152 |
| specimens | 0.338915 |
| adverse events | 0.575289 |
| following tests | 0.432195 |
| previous arrangements | 0.385497 |
| Reporting | 0.317483 |
| shipments | 0.316358 |
| Vaccine Adverse Events | 0.55856 |
| special testing | 0.404585 |
| liver biopsy | 0.502912 |
| Arboviral Diagnostic Reference | 0.467894 |
| Rampart Road | 0.396155 |
| Phone number | 0.392064 |
| Molecular analysis | 0.395545 |
| Healthcare providers | 0.408208 |
|
CLICK HERE |
| 6873 |
Centers for Disease Control and Prevention |
Html |
en |
New Influenza Virus Discovered in Guatemalan Fruit Bats |
New Influenza Virus Discovered in Guatemalan Fruit Bats - CDC |
| South America | 0.274404 |
| lead author | 0.284286 |
| current form | 0.283233 |
| Molecular Virology | 0.277847 |
| journal Proceedings | 0.282394 |
| current threat | 0.292439 |
| Bat flu virus | 0.463073 |
| genetic properties | 0.28078 |
| 20th century | 0.269956 |
| Disease Control | 0.293903 |
| emergency response activities | 0.338641 |
| National Academy | 0.284638 |
| influenza A virus | 0.573365 |
| single host cell | 0.346518 |
| potential source | 0.289891 |
| Preliminary CDC research | 0.387198 |
| Flu web site | 0.349183 |
| global disease detection | 0.430861 |
| global disease experts | 0.339558 |
| CDC’s Division | 0.329793 |
| Influenza related information | 0.524136 |
| different animal | 0.275449 |
| team lead | 0.284575 |
| H1N1 pandemic | 0.275023 |
| Bat influenza viruses | 0.626785 |
|
| new animal species | 0.359181 |
| human health issue | 0.359581 |
| initial laboratory testing | 0.340623 |
| Previous pandemics | 0.27892 |
| United States | 0.27426 |
| human influenza viruses | 0.82471 |
| Viral Diseases | 0.282417 |
| significant changes | 0.274498 |
| study co–author | 0.279639 |
| CDC’s Influenza | 0.510122 |
| Dr. Suxiang Tong | 0.355459 |
| genetic information | 0.280245 |
| complicated chain | 0.280417 |
| Vaccines Branch | 0.276729 |
| little yellow–shouldered bats | 0.349296 |
| bat influenza virus | 0.725982 |
| flu viruses | 0.39 |
| new bat influenza | 0.552065 |
| Pathogen Discovery Program | 0.35467 |
| new virus | 0.36783 |
| Dr. Ruben Donis | 0.342691 |
| influenza viruses | 0.968876 |
| new influenza viruses | 0.63883 |
| humans | 0.344547 |
|
CLICK HERE |
| 7518 |
Centers for Disease Control and Prevention |
Html |
en |
NCEH A to Z Index - K |
Resources for the National Center for Environmental Health |
| MPEG | 0.741242 |
| site | 0.541063 |
| PDF | 0.544429 |
|
|
CLICK HERE |
| 8084 |
Centers for Disease Control and Prevention |
Html |
en |
QuickStats: Motor Vehicle Traffic Death Rates* Among Persons Aged 15-24 Years, by Sex and Age Group - United States, 1999-2011§ |
Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. |
| mmwrq@cdc.gov. | 0.394711 |
| endorsement | 0.33532 |
| Alternate Text | 0.382326 |
| intercensal estimates | 0.39095 |
| Human Services | 0.445179 |
| assistive technology | 0.400023 |
| traffic death rates | 0.703972 |
| motor vehicle traffic | 0.904709 |
| MMWR HTML versions | 0.442292 |
| U.S. Department | 0.441519 |
| electronic PDF version | 0.44015 |
| e-mail | 0.334931 |
| underlying cause | 0.388124 |
| Contact GPO | 0.390757 |
| commercial sources | 0.382725 |
| males | 0.488287 |
| shows motor vehicle | 0.457735 |
| current prices | 0.379075 |
| persons | 0.33293 |
| International Classification | 0.391818 |
| original paper copy | 0.44207 |
| postcensal estimates | 0.391125 |
| United States | 0.386016 |
| original MMWR paper | 0.439874 |
|
| age group | 0.386084 |
| 100,000 | 0.316471 |
| assistance | 0.316995 |
| title | 0.316873 |
| MMWR readers | 0.381716 |
| character translation | 0.379139 |
| file | 0.317076 |
| vehicle traffic death | 0.710302 |
| format errors | 0.376956 |
| females | 0.58289 |
| subject line | 0.398398 |
| Health | 0.326088 |
| typeset documents | 0.380305 |
| trade names | 0.382775 |
| Data | 0.316527 |
| official text | 0.376561 |
| highest rates | 0.461974 |
| non-CDC sites | 0.380163 |
| vehicle traffic deaths | 0.469134 |
| V02–V04 | 0.315886 |
| report | 0.316863 |
| information | 0.317085 |
| Accommodation | 0.316882 |
| electronic conversions | 0.376008 |
|
CLICK HERE |
| 8554 |
Centers for Disease Control and Prevention |
Html |
en |
Chagas Disease - Resources for Health Professionals |
Education and information about Chagas Disease, Triatomine bugs, Kissing Bugs, fact sheets, information for special groups, prevention and control, epidemiology, diagnosis and treatment for Health Professionals. |
| megasyndromes | 0.320366 |
| chronic Trypanosoma cruzi | 0.660113 |
| free access | 0.417996 |
| United States Blood | 0.720638 |
| United States | 0.814504 |
| Vector-borne Transmission | 0.600255 |
| antiparasitic treatment | 0.418585 |
| Transplantation | 0.322059 |
| recent review article | 0.518371 |
| gastrointestinal disease | 0.440931 |
| United States Trypanosoma | 0.785931 |
| thrombus formation | 0.42253 |
| Evidence | 0.345697 |
| cruzi Infection Study | 0.83038 |
| Organ Transplant Recipients | 0.521861 |
| trypanosoma cruzi infection | 0.957259 |
| bundle branch block | 0.544335 |
|
| anterior fascicular block | 0.54753 |
| dilated cardiomyopathy | 0.477965 |
| apical aneurysm | 0.446508 |
| patients | 0.320445 |
| Parasite | 0.359736 |
| clinical disease | 0.444214 |
| American Journal | 0.415015 |
| people | 0.321625 |
| Transplant Working Group | 0.519062 |
| characteristic pathology | 0.427144 |
| States Blood Donors | 0.748331 |
| Congenital Transmission | 0.585384 |
| chagas disease | 0.974943 |
| detailed information | 0.418576 |
| Chagas disease experience | 0.706378 |
| Virginia | 0.343098 |
| conduction abnormalities | 0.445344 |
|
CLICK HERE |
| 9719 |
Centers for Disease Control and Prevention |
Html |
es |
El tabaquismo y el cáncer - Enfermedades & afecciones - Consejos de exfumadores |
La campaña Consejos de exfumadores muestra casos reales de personas que padecen afecciones por fumar o por la exposición al humo de segunda mano. |
| cáncer colorrectal | 0.973198 |
| causa cánceres | 0.549482 |
| CDC ExamÃnese | 0.39389 |
| células madre | 0.705218 |
|
| leucemia mielógena aguda | 0.564738 |
| de la fase | 0.390902 |
| aparato circulatorio | 0.459615 |
| United Ostomy Associations | 0.888105 |
|
CLICK HERE |
| 10436 |
Centers for Disease Control and Prevention |
Html |
en |
The Stroke and Heart Attack Prevention Program (SHAPP) Fact Sheet'Data & Statistics'DHDSP'CDC |
null |
| major risk factor | 0.493096 |
| pressure control rates | 0.66124 |
| heart attack | 0.554171 |
| frequent checkups | 0.497156 |
| Research Triangle Institute | 0.491552 |
| above–average blood pressure | 0.50885 |
| national average.4 Statewide | 0.489747 |
| SHAPP district staff | 0.540444 |
| Evidence–based treatment protocols | 0.49043 |
| easy enrollment | 0.492992 |
| Nurse–driven treatment program | 0.50373 |
| SHAPP treatment | 0.495348 |
| private health insurance | 0.501198 |
| Augusta SHAPP | 0.481943 |
| substantial cost differences | 0.486032 |
| SHAPP advocates | 0.489284 |
| fewer adverse events | 0.487652 |
| SHAPP Annual Report | 0.532166 |
| noteworthy blood pressure | 0.517805 |
| SHAPP patients | 0.497113 |
| Ongoing patient follow–up | 0.482947 |
| SHAPP clinic staff | 0.532267 |
| Cost analyses | 0.491307 |
| blood pressure | 0.945326 |
|
| pressure control rate | 0.512626 |
| patients | 0.54379 |
| blood pressure medication | 0.524676 |
| SHAPP staff | 0.491957 |
| Attack Prevention Program | 0.507161 |
| adverse events | 0.491364 |
| SHAPP programs—in | 0.490555 |
| blood pressure control | 0.723252 |
| improved medication compliance | 0.500902 |
| county health departments | 0.499338 |
| in–depth case studies | 0.492828 |
| total annual costs | 0.487857 |
| best–case scenario group | 0.502971 |
| best–case scenario | 0.616818 |
| treatment scenarios | 0.485085 |
| high blood pressure | 0.901023 |
| preventive medical care | 0.486147 |
| SHAPP clinics | 0.489985 |
| median control rate | 0.500274 |
| Better medication compliance | 0.50568 |
| better blood pressure | 0.515038 |
| SHAPP program | 0.484476 |
| SHAPP clients | 0.518385 |
|
CLICK HERE |
| 12254 |
Centers for Disease Control and Prevention |
Html |
en |
Assessment of Emergency Responders After a Vinyl ChlorideRelease from a Train Derailment - New Jersey, 2012 |
Kimberly Brinker, MSN, MPH1,2, Margaret Lumia, PhD3, Karl V. Markiewicz, PhD4, Mary Anne Duncan, DVM4, Chad Dowell, MS2, Araceli Rey, MPH2, Jason Wilken, PhD1, Alice Shumate, PhD1,3, Jamille Taylor, MPH4, Renée Funk, DVM2 (Author affiliations at end of text). |
| upper respiratory irritation | 0.464593 |
| self-contained breathing apparatus | 0.396264 |
| ongoing health monitoring | 0.430818 |
| exposure monitoring | 0.370298 |
| full-face air-purifying respirator | 0.395307 |
| permissible exposure limit | 0.375872 |
| exposure limit | 0.47691 |
| OSHA respiratory protection | 0.457983 |
| respirator types | 0.383526 |
| Acute exposure | 0.337897 |
| upper respiratory symptoms | 0.634274 |
| train derailment response | 0.436824 |
| lower respiratory irritation | 0.462389 |
| occupational exposure | 0.445517 |
| emergency medical services | 0.460217 |
| respiratory indicators | 0.391554 |
| vinyl chloride exposure | 0.484198 |
| lower respiratory symptoms | 0.464898 |
| respiratory irritation | 0.508181 |
| breathing zone measurements | 0.407227 |
| occupation exposure limit | 0.370962 |
| respiratory protection | 0.981318 |
| hazardous material technicians | 0.423778 |
| chronic occupational exposure | 0.407032 |
|
| local responders | 0.440525 |
| frequently reported symptoms | 0.398416 |
| New Jersey Department | 0.42716 |
| personal protective equipment | 0.555646 |
| respiratory protection program | 0.455474 |
| occupational exposure limits | 0.39245 |
| positive pressure respirator | 0.480515 |
| emergency personnel | 0.347889 |
| chloride exposure levels | 0.482982 |
| personal breathing zone | 0.410721 |
| respondents | 0.442792 |
| air-purifying respirator | 0.410433 |
| Emergency Responder Health | 0.384092 |
| emergency response leaders | 0.574553 |
| vinyl chloride exposures | 0.384811 |
| CDC-recommended exposure limit | 0.373926 |
| exposure risk assessment | 0.369967 |
| particular respirator types | 0.374133 |
| emergency responders | 0.798549 |
| vinyl chloride | 0.686532 |
| OSHA-permissible exposure limit | 0.373973 |
| various emergency response | 0.3705 |
| health effects | 0.348011 |
|
CLICK HERE |